Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 430

1.

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

Chen FL, Xia W, Spector NL.

Clin Cancer Res. 2008 Nov 1;14(21):6730-4. doi: 10.1158/1078-0432.CCR-08-0581. Review.

2.

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL.

Cancer Res. 2006 Feb 1;66(3):1640-7.

3.
4.

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, Moseley MA 3rd, Thompson JW, Chen FL, Koch KM, Spector NL.

Mol Cancer Ther. 2010 Feb;9(2):292-9. doi: 10.1158/1535-7163.MCT-09-1041. Epub 2010 Feb 2.

5.

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

Ito Y, Tokudome N, Sugihara T, Takahashi S, Hatake K.

Breast Cancer. 2007;14(2):156-62. Review.

7.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
9.

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS.

Clin Cancer Res. 2008 Apr 15;14(8):2465-75. doi: 10.1158/1078-0432.CCR-07-4367.

10.

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. Epub 2006 May 8.

11.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL.

J Clin Oncol. 2005 Aug 10;23(23):5305-13. Epub 2005 Jun 13.

PMID:
15955900
12.
13.

An overview of HER-targeted therapy with lapatinib in breast cancer.

McArthur H.

Adv Ther. 2009 Mar;26(3):263-71. doi: 10.1007/s12325-009-0012-y. Epub 2009 Mar 27. Review.

PMID:
19365626
14.

Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.

Chen S, Li X, Feng J, Chang Y, Wang Z, Wen A.

Med Hypotheses. 2011 Aug;77(2):206-8. doi: 10.1016/j.mehy.2011.04.013. Epub 2011 May 12.

PMID:
21570197
15.

Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.

Paul B, Trovato JA, Thompson J.

Am J Health Syst Pharm. 2008 Sep 15;65(18):1703-10. doi: 10.2146/ajhp070646. Review.

PMID:
18768996
16.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
17.

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.

Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK.

Cancer Res. 2007 Oct 15;67(20):9887-93.

18.

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.

Oncogene. 2002 Sep 12;21(41):6255-63.

19.
20.

Target-based therapies in breast cancer: current status and future perspectives.

Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F.

Endocr Relat Cancer. 2009 Sep;16(3):675-702. doi: 10.1677/ERC-08-0208. Epub 2009 Jun 12. Review.

Supplemental Content

Support Center